BRPI0413883A - composição e método para a administração de um composto farmacologicamente ativo a um mamìfero - Google Patents

composição e método para a administração de um composto farmacologicamente ativo a um mamìfero

Info

Publication number
BRPI0413883A
BRPI0413883A BRPI0413883-0A BRPI0413883A BRPI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A
Authority
BR
Brazil
Prior art keywords
active compound
pharmacologically active
compositions
present
mammal
Prior art date
Application number
BRPI0413883-0A
Other languages
English (en)
Inventor
Yerramilli V S N Murthy
Robert H Suva
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of BRPI0413883A publication Critical patent/BRPI0413883A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO E MéTODO PARA A ADMINISTRAçãO DE UM COMPOSTO FARMACOLOGICAMENTE ATIVO A UM MAMìFERO". A presente invenção fornece composições e métodos para ampliar os tempos de liberação e diminuir a toxidez de compostos farmacologicamente ativos. Os compostos consistem num sal do composto farmacologicamente ativo com um íon lipofílico oposto e um solvente farmaceuticamente aceitável imiscível em água. Num modelo, as composições são fornecidas como composições injetáveis. O íon lipofílico oposto pode ser um ácido graxo C~ 8~-C~ 12~,e preferivelmente pode ser um ácido graxo C~ 10~-C~ 18~. As composições são liberadas ao longo do tempo quando administradas a um mamífero. Conseqüentemente, a presente invenção permite que se forneça uma dose de administração controlada do composto ativo por períodos de até 15 dias ou até mais longos. Muitos compostos podem ser administrados de acordo com a presente invenção, incluindo, mas não limitados à tilmicosina, oxitetraciclina, fluoxetina, roxitromicina, e terbinafina.
BRPI0413883-0A 2003-08-27 2004-04-16 composição e método para a administração de um composto farmacologicamente ativo a um mamìfero BRPI0413883A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,262 US20050049210A1 (en) 2003-08-27 2003-08-27 Methods for the controlled delivery of pharmacologically active compounds
PCT/US2004/011823 WO2005025488A2 (en) 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds

Publications (1)

Publication Number Publication Date
BRPI0413883A true BRPI0413883A (pt) 2006-10-24

Family

ID=34217115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413883-0A BRPI0413883A (pt) 2003-08-27 2004-04-16 composição e método para a administração de um composto farmacologicamente ativo a um mamìfero

Country Status (7)

Country Link
US (1) US20050049210A1 (pt)
EP (1) EP1667654A2 (pt)
JP (1) JP2007503433A (pt)
AU (1) AU2004271909A1 (pt)
BR (1) BRPI0413883A (pt)
CA (1) CA2535373A1 (pt)
WO (1) WO2005025488A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
CN101983632A (zh) * 2010-10-11 2011-03-09 西北农林科技大学 一种复方替米考星纳米乳抗菌药物及其制备方法
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
EP2956121B1 (en) * 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN103463480A (zh) * 2013-08-22 2013-12-25 邢波 一种治疗经络阻塞型急性颈部淋巴结炎的中药制备方法
WO2016128991A1 (en) * 2015-02-09 2016-08-18 Cellix Bio Private Limited Compositions and methods for the treatment of mucositis
CN107184553A (zh) * 2017-06-14 2017-09-22 天津佰力喜动物药业有限公司 一种替米考星脂质体分散剂的制备方法
CN108392467A (zh) * 2018-05-30 2018-08-14 山东德信生物科技有限公司 一种替米考星注射液及其制备方法
CN109077999A (zh) * 2018-08-31 2018-12-25 田红卫 一种长效缓释替米考星注射液及其制备方法
CN109655534B (zh) * 2018-11-08 2021-11-30 佛山市正典生物技术有限公司 一种替米考星颗粒含量的检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28875A (en) * 1860-06-26 Improvement in desulphurizing ores and coal
ES488154A0 (es) * 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
JPH0645580B2 (ja) * 1990-10-25 1994-06-15 シェリング・コーポレーション フロルフェニコール、その類似体およびそのオキサゾリン中間体の製造方法
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US6110905A (en) * 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6310053B1 (en) * 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5723447A (en) * 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5766506A (en) * 1996-09-12 1998-06-16 The Dow Chemical Company Hard water compatible phosphate-containing heat transfer fluids
SE511313C2 (sv) * 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US5977133A (en) * 1998-08-19 1999-11-02 Abbott Laboratories Pyridone antibiotic with improved safety profile
US6174540B1 (en) * 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
DE60222803T2 (de) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. Orale kapselformulierung mit verbesserter physikalischer stabilität

Also Published As

Publication number Publication date
EP1667654A2 (en) 2006-06-14
JP2007503433A (ja) 2007-02-22
AU2004271909A1 (en) 2005-03-24
CA2535373A1 (en) 2005-03-24
US20050049210A1 (en) 2005-03-03
WO2005025488A2 (en) 2005-03-24
WO2005025488A3 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
BR0213425A (pt) Composições injetáveis para a liberação controlada de composto farmacologicamente ativo
Heal et al. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety
Marceau et al. Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs
US6368618B1 (en) Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
Cunha et al. The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test
Aljuffali et al. The codrug approach for facilitating drug delivery and bioactivity
KR20050047525A (ko) 담체
Rosenblum et al. Studies in cardiac necrosis: I. Production of cardiac lesions with sympathomimetic amines
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
SA93140384B1 (ar) كربامات الفينيل
BRPI0711482B8 (pt) combinação farmacêutica que compreende 3-(3-dimetilamino-1 etil-2-metil-propil) fenol e uma nsaid
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
AR032730A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
CO6190598A2 (es) Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
BR112013020456B1 (pt) nova composição antifúngica
Sanders et al. Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse
EP1110549A1 (en) Use of trimebutine for treating pain
RS53804A (sr) Parenteralna kompozicija paracetamola
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
BR0013582A (pt) Agonistas retinóides seletivos para rar
Baldessarini et al. Inhibition of catechol-O-methyl transferase by catechols and polyphenols

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.